Malaria Infections and Infestations Malaria
Conditions
Interventions
Chloroquine + sulfadoxine-pyrimethamine versus amodiaquine + sulfadoxine-pyrimethamine versuss amodiaquine + artesunate
Sponsors
Uganda Malaria Surveillance Project (Uganda)
Eligibility
Inclusion criteria
Inclusion criteria: 1. Aged over six months 2. Fever (more than 37.5 ºC axillary) or history of fever in the previous 24 hours 3. Absence of any history of serious side effects to study medications, including allergy to sulfa drugs 4. No evidence of severe malaria or danger signs 5. No evidence of a concomitant febrile illness 6. P. falciparum mono-infection 7. Parasite density more than 2000/ul and less than 200,000/ul 8. Agreement to return for all scheduled follow-up visits 9. Provision of informed consent 10. No history of anti-folate or amodiaquine use in past seven days 11. Absence of pregnancy
Exclusion criteria
Exclusion criteria: Not provided at time of registration
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. 28-day risks for any recurrent infection 2. Recrudescence 3. New infections. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Risk of recurrent infection unadjusted by genotyping at day 14 2. Presence of fever on days one to three 3. Parasitemia on days two and three 4. Change in haemoglobin level between the day of enrolment and the last day of follow-up 5. Presence of gametocytes during any follow-up day 6. Incidence of adverse events | — |
Countries
Uganda
Outcome results
None listed